Compile Data Set for Download or QSAR
maximum 50k data
Found 1366 with Last Name = 'hommel' and Initial = 'u'
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235302(CHEMBL4099771)
Affinity DataKi:  0.00200nMAssay Description:Competitive inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50075098(CHEMBL3414626 | US10143704, Compound A2 | US944606...)
Affinity DataKi:  0.0120nMAssay Description:Competitive inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235302(CHEMBL4099771)
Affinity DataIC50: <0.100nMAssay Description:Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50075098(CHEMBL3414626 | US10143704, Compound A2 | US944606...)
Affinity DataIC50: <0.100nMAssay Description:Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate a...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235301(CHEMBL4081752)
Affinity DataIC50:  0.150nMAssay Description:Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50400274(CHEMBL2180765 | US9085555, 373)
Affinity DataIC50:  1nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEstrogen receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50154137(3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-...)
Affinity DataIC50:  1nMAssay Description:Inhibition of estrogen receptor betaMore data for this Ligand-Target Pair
TargetEstrogen receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50154078(7-Bromo-2-(4-hydroxy-2-methyl-phenyl)-benzooxazol-...)
Affinity DataIC50:  1nMAssay Description:Inhibition of estrogen receptor betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50400273(CHEMBL2180764 | US9085555, 375)
Affinity DataIC50:  2nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170890(US9085555, 318)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50400275(CHEMBL2180766 | US9085555, 127)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170738(US9085555, 166)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170943(US9085555, 371)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170945(US9085555, 374)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170864(US9085555, 292)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254486(US9468661, 64)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254498(US9468661, 109 | US9468661, 76)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171311(US9085555, 741 | US9085555, 757)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171262(US9085555, 692)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171267(US9085555, 697)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235302(CHEMBL4099771)
Affinity DataIC50:  3nMAssay Description:Inhibition of DOT1L in human HeLa cells assessed as reduction in H3K79me2 level after 72 hrs by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254483(US9468661, 61)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171305(US9085555, 735)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170701(US9085555, 129)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254488(US9468661, 66)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170872(US9085555, 300)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170878(US9085555, 306)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171304(US9085555, 734)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171314(US9085555, 744)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171318(US9085555, 748)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171319(US9085555, 749)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171334(US9085555, 764)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235299(CHEMBL4066397)
Affinity DataIC50:  4nMAssay Description:Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235300(CHEMBL4087730)
Affinity DataIC50:  4nMAssay Description:Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235299(CHEMBL4066397)
Affinity DataIC50:  4nMAssay Description:Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone-lysine N-methyltransferase, H3 lysine-79 specific(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50235300(CHEMBL4087730)
Affinity DataIC50:  4nMAssay Description:Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254471(US9468661, 49)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254475(US9468661, 53)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170953(US9085555, 383)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170934(US9085555, 362)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170734(US9085555, 162)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170949(US9085555, 379)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170866(US9085555, 294)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171311(US9085555, 741 | US9085555, 757)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171313(US9085555, 743)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEstrogen receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50154062(2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL...)
Affinity DataIC50:  5nMAssay Description:Inhibition of estrogen receptor betaMore data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254528(US9468661, 106)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171315(US9085555, 745)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171324(US9085555, 754)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171332(US9085555, 762)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 1366 total ) | Next | Last >>
Jump to: